Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes

Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations

Compositions for detecting an infection by an HIV-1 virus

HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies

Methods to improve vector expression and genetic stability

Recombinant viral vectors

Reovirus vaccines and methods of use therefor

Adjuvant

Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain

Chimeric adenoviral vectors

Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties

Vaccine for enveloped viruses

Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein

VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME

HIV consensus envelope sequences and methods for using the same

Chimpanzee adenovirus vaccine carriers

Conformationally stabilized HIV envelope immunogens

METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIES

Antigen delivery vectors and constructs

Immunological Compositions for HIV

METHOD OF USING ADENOVIRAL VECTORS TO INDUCE AN IMMUNE RESPONSE

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

Plasmids and methods for peptide display and affinity-selection on virus-like particles of RNA bacteriophages

MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION

ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE

Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics

Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain

Molecular vaccines for infectious disease

ANTIGEN-ANTIBODY COMPLEXES AS HIV-1 VACCINES

IMMUNOGENIC COMPOSITION AND METHODS

VIRAL POLYPEPTIDES AND METHODS

Chimeric HIV fusion proteins as vaccines

HIV vaccine formulations

VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME

Compositions and methods to treat and control tumors

Method of inducing neutralizing antibodies to human immunodeficiency virus

MIMOTOPES OF HIV ENV

FORMULATION

MUCOSAL BOOSTING FOLLOWING PARENTERAL PRIMING

CHIMERIC MOLECULES

Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region

GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV

Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions

Chimeric Virus Vaccines

HIV CD4 BINDING SITE BASED COVALENT IMMUNOGEN COMPOSITIONS

Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens

NUCLEIC ACID MUCOSAL IMMUNIZATION

Subgenomic replicons of the flavivirus dengue

Simian Adenovirus Vectors and Methods of Use

Recombinant bacterium and methods of antigen and nucleic acid delivery

Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

CD40L vaccines, compositions, and methods related thereto

Antiviral vaccines with improved cellular immunogenicity

METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS

Multiple antigen delivery system using hepatitis E virus-like particle

Peptidic antigen that induces antibody recognizing three-dimensional structure of HIV and method for synthesizing same

Albumin fusion proteins

Biochemically stabilized HIV-1 ENV trimer vaccine

GLYCOPEPTIDE AND USES THEREOF

Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells

Modified HIV-1 Envelope Proteins

Antigen delivery vectors and constructs

Conformationally stabilized HIV envelope immunogens

ANTIGENIC CLOAKING AND ITS USE

Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof

Immunogenic compositions for inducing an immune response to HIV

Compositions and methods for the treatment of viral infections

Gp41 antigens

Splitting GP41

Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

HIV-1 Envelope Polypeptides for HIV Vaccine

Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

HIV-1 Immunogenic Compositions

HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV

Chimeric HIV Antigens

Covalently linked complexes of HIV TAT and ENV PROTEINS

Lentiviral vectors for the preparation of immunotherapeutical compositions

MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF

Mucosal and Systemic Immunization with Alphavirus Replicon Particles

HIV-1 Envelope Based Fragments

Chimpanzee adenovirus vaccine carriers

Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies

Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen

METHOD OF MAKING A VACCINE

COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS

Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine

CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE

POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS

METHODS OF TREATING AND PROTECTING AGAINST HUMAN IMMUNODEFICIENCY VIRUS

METHODS AND REAGENTS FOR VACCINATION WHICH GENERATE A CD8 T CELL IMMUNE RESPONSE

Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine

Multiclade HIV Vaccines

MVA expressing modified HIV envelope, gag, and pol genes

HIV-1 GP41 neutralization domain and use thereof

Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

AEROSOLIZED GENETIC VACCINES AND METHODS OF USE

Chimeric adenoviral vectors

POLYPEPTIDES COMPRISING EPITOPES OF HIV GP41 AND METHODS OF USE

HIV POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM BOTSWANA MJ4

Recombinant Double-Stranded RNA Phage, and Use of the Same

SUGAR IMMUNOGENS

Helper Virus-Free Herpesvirus Amplicon Particles and Uses Thereof

REAGENTS FOR INDUCING AN IMMUNE RESPONSE

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

Self-assembling peptide nanoparticles useful as vaccines

Stereoisomer peptides and their polymer conjugates for HIV disease

Albumin fusion proteins

VIRAL VACCINE VECTORS

Methods of delivery of exogenous proteins to the cytosol and uses thereof

Chimeric HIV-1 Glycoproteins and Their Biological Applications

MULTICOMPONENT VACCINE

COMBINED MUCOSAL AND PARENTERAL IMMUNIZATION AGAINST HIV

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

High Mannose Glycoprotein Epitopes

Subgenomic replicons of the flavivirus dengue

Methods and compositions for liposomal formulation of antigens and uses thereof

CONSTRAINED HIV ENVELOPE-BASED IMMUNOGEN THAT SIMULTANEOUSLY PRESENTS RECEPTOR AND CORECEPTOR BINDING SITES

HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES

RECOMBINANT VIRAL VECTORS

Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction

Recoding method that removes inhibitory sequences and improves HIV gene expression

Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes

Yeast-Based Vaccine for Inducing an Immune Response

Therapeutic peptides and vaccines

Antigen delivery vectors and constructs

Mannose immunogens for HIV-1

Antigen delivery vectors and constructs

Adjuvant compositions and methods of use

HPV vaccines and methods for using the same

ANTI-HIV IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

Methods and reagents for vaccination which generate a CD8 T cell immune response

HIV vaccines based on Env of multiple clades of HIV

Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women

Materials and methods for immunizing against FIV infection

ACUTTE TRANSMITTED HIV ENVELOPE SIGNATURES

Altered Immunogenic Landscape in HIV-1 Envelope Proteins

Immunoenhancer-linked oligomeric HIV envelope peptides

Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate

Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response

Methods of using Fc-cytokine fusion proteins

Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates

Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain

AIDS Vaccine Based on Replicative Vaccinia Virus Vector

Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus

Coiled-coil lipopeptide helical bundles and synthetic virus-like particles

Anti-idiotype monoclonal antibodies mimicking the HIV gp120 CD4-binding (CD4bs)

Methods and reagents for vaccination which generate a CD8 T cell immune response

VACCINE

Recombinant double stranded RNA nucleocapsid and use of the same

ADJUVANT

Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency

Method of using adenoviral vectors to induce an immune response

Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens

Nucleic acids encoding modified South African HIV-1 subtype C gag proteins

HIV VACCINE FORMULATIONS

Modified HIV-1 envelope proteins

Simian adenovirus vectors and methods of use

Immunogens for Vaccines Against Antigenically Variable Pathogens and Diseases

Vaccines against aids comprising cmv/r-nucleic acid constructs

ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA

HIV polynucleotides and polypeptides derived from Botswana MJ4

CHIMERIC HIV FUSION PROTEINS AS VACCINES

Virosome-like vesicles comprising gp41-derived antigens

Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

Methods and reagents for vaccination which generate A CD8 T cell immune response

Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes

Influenza antigen delivery vectors and constructs

Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization

HIV VACCINE

Genetic constructs and compositions comprising RRE and CTE and uses thereof

Molecular scaffolds for HIV-1 immunogens

Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain

Antibody production elicited by a DNA vaccine delivered by electroporation

Immunizing Against HIV Infection

Multivalent Immunogen

Method of inducing high-titer neutralizing antibody responses in a host by administering immune complexes comprising anti-HIV-1 Env antibodies and the HIV-1 Env

Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens

Use of microparticles combined with submicron oil-in-water emulsions

Albumin Fusion Proteins

Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies

Albumin Fusion Proteins

PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE

Immunostimulatory Combinations for Vaccine Adjuvants

DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40

Modified Adenovirus Hexon Protein and Uses Thereof

MVA expressing modified HIV envelope, gag, and pol genes

Immunological compositions

Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery

Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications

Advanced genetic vaccines

Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof

Renta: an HIV immunogen and uses thereof

Covalently-linked complexes of HIV Tat and Env proteins

HIV vaccines based on Env of multiple clades of HIV

INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE

T4 bacteriophage bound to a substrate

Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex

Hiv Gp-41-Membrane Proximal Region Arrayed On Hepatitis B Surface Antigen Particles as Novel Antigens

Live virus vaccines

Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby

Albumin fusion proteins

Soluble and stabilized trimeric form of gp41 polypeptides

Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors

Env polypeptide complexes and methods of use

Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

Sugar immunogens

Albumin Fusion Proteins

Albumin fusion proteins comprising insulin polypeptides

Albumin Fusion Proteins

Vaccine delivery compositions and methods of use

G-CSF-albumin fusion proteins

Albumin fusion proteins

Methods of inducing mucosal immunity

Directional induction of immune response by co-administration of antigens with chemokines

VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR THE IMMUNIZATION AGAINST HIV

POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES, AND USES THEREOF

Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades

Adenoviral Vector Compositions

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen

Microparticles for delivery of heterologous nucleic acids

Yeast-based vaccine for inducing an immune response

Polynucleotides encoding modified HIV-1 gp41 membrane polypeptides

Immunogenic proteoliposomes, and uses thereof

Chimeric adenoviral vectors

Albumin fusion proteins

Immunomodulating Compositions, Uses Therefore and Processes for Their Production

Albumin fusion proteins

Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity

HIV-1 glycopeptides and derivatives; preparation and applications thereof

Method of Using Adenoviral Vectors to Induce an Immune Response

Mucosal boosting following parenteral priming

VIRAL GENE PRODUCTS AND METHODS FOR VACCINATION TO PREVENT VIRAL ASSOCIATED DISEASES

Rice plant having vaccine gene transferred thereinto

Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv

Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins

Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein

process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof

Immunogenic compositions comprising human immunodeficiency virus type 2 (HIV-2) glycosylated and unglycosylated envelope proteins and their methods of preparation

Combination approaches for generating immune responses

Method for modulating the binding activity of a novel ICAM-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes

Immunogenic composition and methods

Vaccines, immunotherapeutics and methods for using the same

Immunogenic compositions and methods of use

Hiv polynucleotides and polypeptides derived from botswana mj4

Antibodies with simultaneous subsite specificities to protein and lipid epitopes

Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity

Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications

Compositions and methods for generating an immune response

Compositions and methods to treat and control tumors by loading antigen presenting cells

Method of making modified immunodeficiency virus particles

Hepatitis C virus non-structural NS3/4A fusion gene

Method

DNA vaccines encoding antigen linked to a domain that binds CD40

Adjuvant combination formulations

HIV-1 protein associated with broadly reactive neutralizing antibody response

Therapeutic peptides and vaccines

Modulation of negative immune regulators and applications for immunotherapy

Albumin fusion proteins

HIV vaccines based on Env of multiple clades of HIV

Recombinant double-stranded RNA phage, and use of the same

Modulation of cytokine signaling regulators and applications for immunotherapy

Carrier of a diamond fine particle for immobilizing virus

Mannose immunogens for HIV-1

Use of HIV-1 gp120 and gp160 proteins modified in the V3 loop for the preparation of vaccine compositions and formulations containing the same

ANTI-HIV IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

Gp120 specific antigens and uses thereof

Prostate specific antigens and uses thereof

Virus vaccine

Compositions and methods for delivery of genetic material

Virus-like particles, methods of preparation, and immunogenic compositions

Therapeutic immunization of hiv-infected individuals

Immunogen

Albumin fusion proteins

Vaccines containing ribavirin and methods of use thereof

Gp41 inhibitor

Method of inducing an enhanced immune response against hiv

Antigenic peptides

Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

Materials and methods for immunizing against FIV infection

Recombinant double-stranded RNA phages and uses thereof

Pharmaceutical compositions comprising an hiv envelope protein and cd4

Genetic constructs and compositions comprising RRE and CTE and uses thereof

Combination gene delivery vehicles

Methods and compositions for inhibiting hiv-coreceptor interactions

Replication-competent adenoviral vectors

Hiv vaccine formulations

Immunogens for hiv vaccine

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

Hepatitis C virus non-structural NS3/4A fusion gene

Induction of cytotoxic T-lymphocyte responses

Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

DNA expression vectors and methods of use

Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods

Antigen library immunization

Antigen delivery vectors and constructs

Immunizing against HIV infection

Recombinant lentivirus encoding modified GP 120 signal sequences

Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS